These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32208930)

  • 1. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
    Wang M; Wang T; Zhang X; Wu X; Jiang S
    Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
    Liang H; Du J; Elhassan RM; Hou X; Fang H
    Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
    [No Abstract]   [Full Text] [Related]  

  • 3. CDK7 inhibitors as anticancer drugs.
    Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
    Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
    Diab S; Yu M; Wang S
    J Med Chem; 2020 Jul; 63(14):7458-7474. PubMed ID: 32150405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
    Fisher RP
    Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
    Teng Y; Lu K; Zhang Q; Zhao L; Huang Y; Ingarra AM; Galons H; Li T; Cui S; Yu P; Oumata N
    Eur J Med Chem; 2019 Dec; 183():111641. PubMed ID: 31514062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
    Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
    Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
    Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
    Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7).
    Ji W; Du G; Jiang J; Lu W; Mills CE; Yuan L; Jiang F; He Z; Bradshaw GA; Chung M; Jiang Z; Byun WS; Hinshaw SM; Zhang T; Gray NS
    Eur J Med Chem; 2024 Oct; 276():116613. PubMed ID: 39004018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
    Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
    Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
    Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
    Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
    Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
    Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
    Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
    Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
    Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
    Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
    Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
    ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
    Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
    Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer.
    Choi YJ; Lee H; Kim DS; Kim DH; Kang MH; Cho YH; Choi CM; Yoo J; Lee KO; Choi EK; Lee JC; Rho JK
    Eur J Pharmacol; 2021 Sep; 907():174298. PubMed ID: 34224696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
    Song X; Fang C; Dai Y; Sun Y; Qiu C; Lin X; Xu R
    Br J Cancer; 2024 May; 130(8):1239-1248. PubMed ID: 38355840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of drug candidature: In silico ADMET, binding interactions with CDK7 and normal cell line studies of potentially anti-breast cancer enamidines.
    Bansode P; Anantacharya R; Dhanavade M; Kamble S; Barale S; Sonawane K; Satyanarayan ND; Rashinkar G
    Comput Biol Chem; 2019 Dec; 83():107124. PubMed ID: 31563021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.